Item 7.01. Regulation FD Disclosure.
On October 12, 2022, Nemaura Medical, Inc. (the “Company”)
issued a press release announcing receipt of a provisional purchase order from TPMENA, the Company’s Middle East/North Africa licensee
for the Company’s sugarBEAT® system. TPMENA issued the provisional purchase order following its regulatory registration submission
for sugarBEAT® in the Kingdom of Saudi Arabia (“KSA”). Registration in KSA is anticipated in the first quarter of 2023.
The purchase order is contingent on receipt of KSA registration.
The information included in this Current Report on
Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information
be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such a filing. The information set forth under this Item 7.01 shall not be deemed an admission
as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements
of Regulation FD.
DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS
Certain statements contained in this Current Report
on Form 8-K, including on Exhibit 99.1, that are not historical facts constitute forward-looking statements. Reliance should not be placed
on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which may cause actual results,
performance, or achievements to differ materially from those expressed or implied. Any forward-looking statement speaks only as of the
date made. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date on which
they are made.
The words "believe,"
"anticipate," "design," "estimate," "plan," "predict," "seek," "expect,"
"intend," "may," "could," "should," "potential," "likely," "projects,"
"continue," "will," and "would" and similar expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying words. These forward-looking statements are not guarantees of
the future as there are a number of meaningful factors that could cause the Company’s actual results to vary materially from
those indicated by such forward-looking statements. These statements are based on certain assumptions made based on experience,
expected future developments and other factors the Company believes are appropriate in the circumstances. Factors which could cause
actual results to differ from expectations, many of which are beyond the Company’s control, include, but are not limited to,
obtaining regulatory approval for our sugarBEAT device, conducting successful clinical trials, executing agreements required to
successfully advance the Company's objectives; retaining the management and scientific team to advance the product; overcoming
adverse changes in market conditions and the regulatory environment; obtaining and enforcing intellectual property rights; obtaining
adequate financing in the future through product licensing, public or private equity or debt financing or otherwise; dealing with
general business conditions and competition; and other factors referenced in the Company’s filings with the Securities and
Exchange Commission, including in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the
fiscal year ended March 31, 2022, as the same may be updated from time to time. There can be no assurance that the KSA will
approve the registration. Except as required by law, we do not assume any obligation to update any forward-looking statement. We
disclaim any intention or obligation to update or revise any forward-looking statement, whether as a result of new information,
future events or otherwise.